Humedix Co., Ltd. (200670) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Humedix Co., Ltd. (200670:KRX), powered by AI.

Current Price
₩28,800
P/E Ratio
6.1
Market Cap
317.8B
Sector
Healthcare
What is the Humedix Co., Ltd. stock price forecast?

Humedix Co., Ltd. is currently trading at ₩28,800. View real-time AI analysis on Alpha Lenz.

What is Humedix Co., Ltd. insider trading activity?

View the latest insider trading data for Humedix Co., Ltd. on Alpha Lenz.

What is Humedix Co., Ltd.'s P/E ratio?

Humedix Co., Ltd.'s P/E ratio is 6.1.

Humedix Co., Ltd.

KRX · 200670
₩28,800+500(+1.77%)Market closedKRX regular session 09:00–15:30 KST
Ask about Humedix Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Humedix Co., Ltd. trades at a P/E of 6.1 (undervalued) with strong ROE of 19.6%. 3Y revenue CAGR of 11.3% highlights clear growth momentum.

Ask for details

Company Overview

Humedix Co., Ltd. is a promising biopharmaceutical company primarily focused on the development, production, and distribution of medical and healthcare products. This South Korean firm has carved out a niche in the global market by specializing in aesthetic and therapeutic solutions, particularly pioneering advancements in dermal fillers and hyaluronate-based pharmaceuticals. Its portfolio prominently features items aimed at enhancing skin health and medical devices utilised in plastic surgery and ophthalmology. Humedix plays a crucial role in the healthcare sector, contributing to both the enhancement of medical treatments and aesthetic procedures. Its innovative products have gained significant traction, fostering a reputation for quality and effectiveness in the medical community. The company’s commitment to research and development underpins its status in the pharmaceutical industry, aiming to bring about positive health outcomes and improved quality of life for patients. As a key player in the regional market, Humedix Co., Ltd. continues to expand its influence, driving both industry growth and innovation in medical technology.

CEO강민종
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩317,807,019,000Market Cap
₩170,052,787,100Revenue
11.23MShares Out
0Employees

Margins

46.76%Gross
35.20%EBITDA
24.89%Operating
37.53%Pre-Tax
30.45%Net

Valuation

6.14P/E
1.06P/B
1.87EV/Sales
4.67EV/EBITDA
8.56P/FCF

Growth (CAGR)

11.35%Rev 3Yr
11.54%Rev 5Yr
17.58%Op Inc 3Yr
20.53%Op Inc 5Yr
34.77%Net Inc 3Yr
24.64%Net Inc 5Yr

Returns

18.06%ROA
19.61%ROE
22.28%ROIC

Financial Health

₩39,878,372,970Cash & Cash Equivalents
₩-15,827,593,130Net Debt
8.03%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Humedix Co., Ltd. (ticker: 200670) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $317.8B.

The current price is ₩28,800 with a P/E ratio of 6.14x and P/B of 1.06x.

ROE is 19.61% and operating margin is 24.89%. Annual revenue is $170.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Humedix Co., Ltd. (200670) Stock Forecast 2026 ₩28,800 — Price, Financials & Analyst Targets | Alpha Lenz